{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-109809","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-09-23T11:10:29+00:00","discovered_at":"2026-09-23T11:15:17.291165+00:00","generated_at":"2026-09-23T11:15:28.160660+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Armata receives $3.7M additional DoW funding for AP-SA02 Phase 3; total $32.4M","bullets":["Received $3.7M non-dilutive funding from U.S. Department of War for AP-SA02 Phase 3 development.","Cumulative DoW funding under award now $32.4M, adding to $28.7M previously provided.","Funding supports adjunctive treatment for complicated S. aureus bacteremia (MSSA/MRSA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-109809","json":"https://secwatch.observer/filing/0001104659-26-109809.json","markdown":"https://secwatch.observer/filing/0001104659-26-109809.md","text":"https://secwatch.observer/filing/0001104659-26-109809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926109809/0001104659-26-109809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926109809/tm2625977d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T11:15:28.160660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}